Drug delivery devices and methods

Patent metadata

Field	Value
Publication number	US-11992583-B2
Application number	US-202117158322-A
Country	US
Kind code	B2
Filing date	Jan 26, 2021
Priority date	May 12, 2014
Publication date	May 28, 2024
Grant date	May 28, 2024

Abstract

Drug delivery devices are provided in which much of a drug payload within the device remains within an area proximal to a wall of the device through which the drug must pass for release of the drug from the device into a patient. In one case, the device may include a drug reservoir portion which has a drug reservoir lumen bounded by a reservoir wall having an inner surface; a drug located in the drug reservoir lumen; and a core region which does not comprise the drug, wherein the drug is disposed between the inner surface of the reservoir wall and the core region. The device may be elastically deformable between a first shape suited for insertion through a lumen into a body cavity of the patient and a second shape suited to retain the device within the body cavity.

First claim

We claim:

1. A drug delivery device for insertion into the body of a patient, the drug delivery device comprising:
a drug reservoir portion which comprises a drug reservoir lumen bounded by reservoir walls which comprise a drug permeable and water permeable polymeric material;
a retention frame lumen in which a retention frame is disposed; and
a drug formulation which comprises a drug and which substantially fills the drug reservoir lumen,
wherein the drug reservoir lumen has a ribbon shape such that a substantial portion of the drug formulation is adjacent to the reservoir walls to facilitate trans-wall diffusion of the drug through the reservoir walls, and
wherein the drug delivery device is elastically deformable between a first shape configured to be inserted through a urethra into a bladder of the patient and a second shape, induced by the retention frame, configured to retain the entire drug delivery device within the bladder.

2. The drug delivery device of claim 1 , wherein the reservoir walls are dimensioned to define the ribbon-shaped drug reservoir lumen to have a maximum width:maximum height ratio of at least 4:1.

3. The drug delivery device of claim 1 , wherein the reservoir walls are dimensioned to define the ribbon-shaped drug reservoir lumen to have a maximum width:maximum height ratio of at least 7:1.

4. The drug delivery device of claim 1 , wherein the reservoir walls are dimensioned to define the ribbon-shaped drug reservoir lumen to have a maximum width:maximum height ratio of at least 10:1.

5. The drug delivery device of claim 1 , wherein the second shape is a coil shape, a spiral shape, or a serpentine shape.

6. The drug delivery device of claim 1 , wherein the drug formulation is in the form of a powder or granules.

7. The drug delivery device of claim 1 , wherein the reservoir walls comprise a water-permeable elastomeric material.

8. The drug delivery device of claim 7 , wherein the water-permeable elastomeric material comprises silicone, a polyurethane, or a combination thereof.

9. The drug delivery device of claim 1 , wherein the drug formulation is in the form of a powder or granules, and the reservoir walls comprise a water-permeable elastomeric material and are dimensioned to define the ribbon-shaped drug reservoir lumen having a maximum width:maximum height ratio of at least 4:1.

10. The drug delivery device of claim 1 , wherein the reservoir walls comprise the retention frame lumen in which the retention frame is disposed.

11. The drug delivery device of claim 1 , wherein the reservoir walls define an exterior surface of the drug delivery device.

12. A method of administering a drug to a patient in need thereof, comprising:
inserting into the patient the drug delivery device of claim 1 ; and
permitting the drug to be released from the drug delivery device.

13. The method of claim 12 , wherein the drug delivery device is inserted into the patient's urinary bladder via through the patient's urethra.

14. An intravesical drug delivery device, the intravesical drug delivery device comprising:
a drug reservoir portion which comprises a drug reservoir lumen bounded by reservoir walls which comprise a drug permeable and water permeable elastomeric material; and
a drug formulation in a solid form, which comprises a drug and which substantially fills the drug reservoir lumen,
wherein the drug reservoir lumen has a ribbon shape such that a substantial portion of the drug formulation is adjacent to the reservoir walls to facilitate trans-wall diffusion of the drug through the reservoir walls,
wherein the intravesical drug delivery device is elastically deformable between a first shape, which is a relatively straightened shape configured to be inserted through a patient's urethra, and a second shape, which is configured to retain the intravesical drug delivery device within the patient's bladder, and
wherein the reservoir walls are dimensioned to define the ribbon-shaped drug reservoir lumen to have a maximum width:maximum height ratio of at least 4:1.

15. The intravesical drug delivery device of claim 14 , wherein the second shape is a coil shape, a spiral shape, or a serpentine shape.

16. The intravesical drug delivery device of claim 14 , wherein the reservoir walls define an exterior surface of the intravesical drug delivery device.

17. The intravesical drug delivery device of claim 14 , further comprising a retention frame lumen in which a retention frame is disposed.

Assignees

• Taris Biomedical Llc

Inventors

• Lee Heejin
• Daniel Karen
• Larrivee-Elkins Cheryl
• Agarwal Vikas
• Ho Duc Hong Linh

Classifications

• A61L29/06 Primary

  obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds · CPC title

• A61K9/0034

  Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants · CPC title

• A61K9/14

  Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)} · CPC title

• A61K9/20

  Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)} · CPC title

• A61K31/167

  having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol · CPC title